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Abstract 
Background: The nucleocapsid (NC) domain of HIV‑1 Gag is responsible for specific recognition and packaging of 
genomic RNA (gRNA) into new viral particles. This occurs through specific interactions between the Gag NC domain 
and the Psi packaging signal in gRNA. In addition to this critical function, NC proteins are also nucleic acid (NA) chap‑
erone proteins that facilitate NA rearrangements during reverse transcription. Although the interaction with Psi and 
chaperone activity of HIV‑1 NC have been well characterized in vitro, little is known about simian immunodeficiency 
virus (SIV) NC. Non‑human primates are frequently used as a platform to study retroviral infection in vivo; thus, it is 
important to understand underlying mechanistic differences between HIV‑1 and SIV NC.
Results: Here, we characterize SIV NC chaperone activity for the first time. Only modest differences are observed in 
the ability of SIV NC to facilitate reactions that mimic the minus‑strand annealing and transfer steps of reverse tran‑
scription relative to HIV‑1 NC, with the latter displaying slightly higher strand transfer and annealing rates. Quantitative 
single molecule DNA stretching studies and dynamic light scattering experiments reveal that these differences are 
due to significantly increased DNA compaction energy and higher aggregation capability of HIV‑1 NC relative to the 
SIV protein. Using salt‑titration binding assays, we find that both proteins are strikingly similar in their ability to specifi‑
cally interact with HIV‑1 Psi RNA. In contrast, they do not demonstrate specific binding to an RNA derived from the 
putative SIV packaging signal.
Conclusions: Based on these studies, we conclude that (1) HIV‑1 NC is a slightly more efficient NA chaperone protein 
than SIV NC, (2) mechanistic differences between the NA interactions of highly similar retroviral NC proteins are 
revealed by quantitative single molecule DNA stretching, and (3) SIV NC demonstrates cross‑species recognition of 
the HIV‑1 Psi RNA packaging signal.
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Background
AIDS, a devastating disease that emerged in the late 
twentieth century, is caused by two lentiviruses: HIV-1 
[1–3] and HIV-2 [4]. Early on, there was intense inter-
est in the origin of these viruses and the AIDS pandemic, 
which by 2014 led to infection of 76.2 million people 
(UNAIDS 2014 estimates, P.D. Ghys, personal commu-
nication). Molecular and phylogenetic analyses of fecal 
samples collected from the forest floor, primarily in 
southern Cameroon, demonstrated that HIV-1 infection 
of humans resulted from cross-species transmission of 
a chimpanzee simian immunodeficiency virus (SIVcpz), 
a recombinant generated from two distinct monkey SIV 
lineages [5, 6] (reviewed in [7, 8]). HIV-2 was transmit-
ted to humans by an SIV from sooty mangabeys (SIVsm) 
[9–11]. Interestingly, SIVmac [12, 13], a strain used in 
non-human primate model systems (including the pre-
sent work), was acquired unexpectedly by transmission 
of SIVsm from sooty mangabeys to rhesus macaques at 
the California National Primate Research Center, where 
both groups of animals were housed [14, 15].
Like other retroviruses, SIV and HIV-1 have a nucle-
ocapsid protein (NC), a small basic structural protein 
containing two zinc-binding domains, i.e., zinc fingers 
(ZFs), each with the invariant CCHC motif, connected 
by a short basic flexible peptide (Fig. 1a) [16–20]. NC is 
generated by viral protease (PR)-mediated cleavage of the 
Gag precursor protein during virus maturation [21–24]. 
For HIV-1, it has been shown that the NC domain in Gag 
is essential for specific recognition of the Psi packaging 
element in genomic RNA (gRNA) [25–31] and tRNALys3 
primer placement on gRNA [32–34].
Retroviral NC proteins are nucleic acid (NA) chap-
erones, i.e., they remodel NA structures to facilitate 
formation of the most thermodynamically stable con-
formations [35] (reviewed in refs. [17–19, 36, 37]). This 
activity is critical for ensuring specific and efficient 
reverse transcription, including initiation [38, 39], as well 
as the minus- and plus-strand transfer reactions [18, 19, 
37]. For example, in the minus-strand transfer step, NC 
facilitates annealing of the complementary repeat regions 
(R, r), which contain the highly structured transactivation 
response element (TAR) in gRNA and its minus-strand 
DNA complement, respectively [18, 19, 40].
Effective chaperone activity consists of three com-
ponents: (1) NA aggregation, which is important for 
NA annealing (associated with the basic residues); (2) 
moderate helix destabilizing activity (associated with 
the ZFs); and (3) rapid on–off NA binding kinetics [41] 
(reviewed in refs. [18, 19]). In fact, the relatively weak NA 
chaperone activity of the HIV-1 Gag and NCp9 precur-
sor proteins compared with that of mature NC can be 
attributed to their slow dissociation kinetics from bound 
NA [42–46]. Recent work on the molecular mechanism 
Fig. 1 Sequence and structural features of HIV‑1 and SIV NC proteins. a Schematic diagrams of NC proteins: HIV‑1 NL4‑3 NC and SIVmne NC. Basic 
residues are colored blue, acidic residues are colored red, the CCHC residues that coordinate the Zn2+ ions in the ZFs are colored gray, and the aro‑
matic residue in each finger is underlined. The numbering is based on the sequence of the mature NC protein in each case. b Sequence alignment 
of HIV‑1 and SIV NC proteins. Coloring and underlining are the same as in (a). The boxes indicate the sequence comprising each ZF
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responsible for NC-facilitated duplex destabilization has 
focused on structural elements required for murine leu-
kemia virus (MLV) gRNA dimerization [47], as well as 
destabilization of HIV-1 TAR DNA [48], TAR RNA [49, 
50], and full-length (−) strong-stop DNA ((−) SSDNA), 
which contains all of r and the complement of the unique 
5′ sequence (u5) [51]. These studies have emphasized the 
importance of ZF-dependent binding of specific G bases 
and contributions of unstable stem structures with mis-
matched bases, bulges, and loop regions.
Not surprisingly, given the simian origin of HIV-1, SIV 
NC shares 53% amino acid sequence identity with the 
HIV-1 protein (Fig.  1). Early work demonstrated that 
both SIV from Macaca nemestrina (SIVmne) and HIV-1 
NCs had very similar NA binding properties in stud-
ies with model oligo- and polynuclotide substrates [52]. 
Moreover, the NMR solution structure of SIVl’hoest NC 
(residues 13–51) showed that the overall structures of 
SIV and HIV-1 NC are also very similar, despite several 
amino acid sequence differences in the ZFs and structural 
differences in the flexible linker [53]. The ability of SIV 
NC to coordinate Zn2+ is required for efficient replica-
tion in cell-based assays [54, 55], Gag processing [55, 56], 
proper core condensation and NC protein stability [56], 
as well as RNA packaging, although to a lesser extent 
than for MLV and HIV-1 [54, 55]. In contrast to HIV-1 
NC, ZF2 of SIV NC appears to be slightly more impor-
tant than ZF1 [55, 56]. Interestingly, compared with the 
HIV-1 protein, the chaperone activity of HIV-2 NC is not 
as robust, likely due, at least in part, to the shorter HIV-2 
N-terminal basic region [57].
In this study, we provide an in-depth analysis of the 
chaperone activities of SIV and HIV-1 NCs in the con-
text of biologically relevant reactions: the minus-strand 
transfer step in reverse transcription and selective bind-
ing to the Psi packaging element. Using a variety of bio-
chemical and biophysical (e.g., single molecule DNA 
stretching and dynamic light scattering) approaches, 
we show that the slightly higher activity of HIV-1 NC 
in the annealing reaction in minus-strand transfer can 
be explained by the greater aggregation activity of the 
HIV-1 protein relative to SIV NC. Salt-titration assays 
show that both NC proteins have a similar balance of 
electrostatic and specific binding contacts with NAs 
and both can distinguish HIV-1 Psi RNA from non-Psi 
sequences. However, neither protein is capable of spe-
cific binding to the putative SIV RNA packaging signal 
tested here. Overall, while most of the NA binding and 
chaperone activities of HIV-1 and SIV NC are similar, 
our analysis reveals mechanistic differences that provide 
unique information regarding the replication strategies 
of HIV-1 and SIV.
Results
Comparison of SIV and HIV‑1 NC proteins and predicted 
secondary structures of TAR and Psi RNAs
The sequences of the SIV and HIV-1 NC proteins are 
compared in Fig.  1. Both proteins are highly basic and 
have two ZF domains containing conserved CCHC 
motifs and aromatic residues. However, HIV-1 NC is 
more basic than SIV NC over a wide range of pH; at pH 
7, for example, the estimated charge for HIV-1 is 11.2 
and for SIV, 10.2. Additionally, ZF1 of SIV NC has a Trp 
residue, whereas the corresponding amino acid in HIV-1 
NC is Phe. This difference is expected to be minor, since 
mutation of F16 to W has little effect on HIV-1 NC NA 
chaperone activity and intravirion reverse transcription 
and no effect on infectivity [58].
During the course of virus replication, the HIV-1 NC 
protein interacts with structured RNA elements present 
at the 5′ end of the viral genome: the TAR stem-loop (SL), 
which is at the extreme 5′ end of R in gRNA (Fig. 2a) and 
is involved in the minus-strand transfer step of reverse 
transcription (reviewed in refs. [18, 19, 40]); and the Psi 
region, composed of three SLs, which contributes to the 
dimerization and packaging of gRNA and has been stud-
ied extensively [25, 59, 60]. The SL structures include 
SL1, which contains the dimerization initiation site (DIS) 
and two bulges, SL2 containing the major 5′ splice donor 
site; and SL3, which is important for packaging viral RNA 
(Fig. 2b). The earlier studies showed that while SL1-3 are 
all necessary for efficient gRNA encapsidation, SL1 and 
SL3 play a larger role than SL2. The RNA sequence that 
constitutes the SIV Psi element has not been studied to 
the same extent as that of HIV-1. The available informa-
tion suggests that SIV and HIV-1 Psi share a similar sec-
ondary structure and that this region is also critical for 
SIV gRNA packaging [61–63] (Fig. 2d).
In the binding and small angle scattering (SAXS) exper-
iments described below, we used an HIV-1 TARpolyA 
construct (Fig. 2a) to more closely match the longer and 
more complex SIV TAR structure (Fig. 2c) [63, 64]. Note 
that although the overall predicted secondary structures 
of HIV-1 and SIV Psi are similar (Fig. 2b, d, respectively), 
SIV Psi is 40 nucleotides (nt) longer than HIV-1 Psi, with 
significantly longer predicted SL1 and SL3 stem regions.
Minus‑strand annealing and strand transfer activities 
of SIV and HIV‑1 NCs
In view of the critical role of NC chaperone activity in 
reverse transcription [18, 19, 37], we investigated the 
activity of SIV and HIV-1 NCs in model systems that 
recapitulate the reactions required for minus-strand 
transfer (Fig. 3a). In the initial step, a DNA oligonucleo-
tide representing (−) SSDNA (derived from sequences 
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complementary to the 5′ end of the genome) is annealed 
to an RNA transcript representing the acceptor RNA 
(derived from sequences at the 3′ end of the genome) 
(Annealing). The annealed DNA is then extended by 
reverse transcriptase (RT) to give the transfer product 
(Minus-Strand Transfer). Note that in our systems, the 
minus-strand transfer assay includes the annealing step 
as well as DNA elongation.
To compare the annealing activities of the two NCs 
(Fig. 3), we evaluated reactions containing SIV substrates 
and either SIV NC (Fig. 3b-1) or HIV-1 NC (Fig. 3b-2), 
as well as reactions with HIV-1 substrates and SIV NC 
(Fig.  3c-1) or HIV-1 NC (Fig.  3c-2). Representative gels 
can be found in Additional file 1: Fig. S1. As the NC con-
centration was increased, the extent of annealing was 
also increased. For example, when 1.25 µM NC was used 
to measure SIV annealing, the percent annealed prod-
uct was  ~  60% with both NCs, but at 5.0  µM NC, pla-
teau values of almost 80% were reached (Fig. 3b-1, b-2). 
In general, at the 30 min end point, the percent annealed 
DNA was very similar for reactions with SIV or HIV-1 
NC; in some cases the values obtained with HIV-1 NC 
(with either substrate set) were slightly higher than the 
values observed with SIV NC, but the difference was 
never greater than ~1.4-fold (e.g., reaction with HIV-1 
substrates and NC at 0.65 µM: compare data in Fig. 3c-1 
(31%) and Fig. 3c-2 (42%)).
In contrast, comparison of the rates of annealing 
showed small, but more significant differences between 
the activities of the two NCs (Table  1a). Thus, with the 
SIV substrates, the rate of annealing with HIV-1 NC 
was ~ 3-fold higher than the rate with SIV NC, whereas 
with the HIV-1 substrates, the difference was  ~  2-fold. 
SIV NC appeared to be somewhat more active with the 
HIV-1 substrates, but HIV-1 NC had the same activity in 
both systems.
Minus-strand transfer was tested next, initially in reac-
tions with SIV substrates and either SIV or HIV-1 NC 
(Fig.  4). The gel images clearly show bands correspond-
ing to the transfer product and (−) SSDNA (Fig. 4a). As 
was observed for annealing, the end point values for SIV 
minus-strand transfer were similar for reactions with SIV 
(Fig. 4b) or HIV-1 (Fig. 4c) NC. For example, at 1.25 µM 
NC, the percent strand transfer with SIV NC was 42% 
and with HIV-1 NC, it was 51%. At 5  µM, the plateau 
values were 57% (SIV NC) and 70% (HIV-1 NC). Again, 
there was a small, but more significant difference in the 
reaction rates with the two NCs. With 1.25  µM HIV-1 
NC, the rate was 2.3-fold greater than with SIV NC at the 
same concentration. (Table 1b). Not surprisingly, minus-
strand transfer with the HIV-1 substrates was slightly 
more efficient than with the SIV substrates, but in this 
case too, the end point values with 1.25  µM NC were 
Fig. 2 Sequence and mfold‑predicted secondary structure of TAR 
and Psi RNA constructs used in this study. a HIV‑1 TARpolyA. b HIV‑1 
Psi. c SIVmac TAR. d SIVmac Psi. In all cases, numbering refers to the 
nt position in gRNA. The box in (a) indicates HIV‑1 TAR RNA. The boxes 
in (b, d) indicate the ∆DIS mutation, where DIS loop residues are 
replaced with a GNRA‑type tetraloop (GAGA) to eliminate dimeriza‑
tion
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very similar (51%, SIV NC; 64%, HIV-1 NC) (Additional 
file 2: Fig. S2). The rate of the reaction was 2.6-fold higher 
with HIV-1 NC (Table 1b).
Single molecule DNA stretching experiments
To further understand differences between HIV-1 NC 
and SIV NC, we tested the force-extension (stretch and 
return) curves of single DNA molecules as a function 
of protein concentration for both proteins. As shown 
in Fig.  5a, the shapes and qualitative characteristics of 
the force-extension curves were very similar. To quan-
tify these characteristics, we calculated the transition 
slope, which reflects the degree of intercalative bind-
ing by NC to DNA, and the hysteresis area ratio, which 




Fig. 3 Kinetics of minus‑strand annealing with SIV and HIV‑1 substrates in the presence of SIV and HIV‑1 NC proteins. a Reconstituted system 
used to assay minus‑strand annealing and transfer. The diagram shows the acceptor RNA with a portion of U3 and the R sequence at the 3′ end of 
the viral genome annealed to (−) SSDNA with the complementary r sequence and a portion of u5, complementary to the U5 sequence. For the 
SIV substrates, the nt lengths of u5, R/r, and U3 sequences are as follows: u5, 20 nt; R/r, 176 nt; and U3, 52 nt. For the HIV‑1 substrates, the lengths 
are: u5, 34 nt; R/r, 94 nt; and U3, 54 nt. The asterisk indicates that the (−) SSDNA is labeled at its 5′ end with 32P. Annealing of the complementary 
R regions is indicated by vertical lines. The U3 sequence serves as the template for RT‑catalyzed extension of annealed (−) SSDNA. The final DNA 
transfer product is 248 nt (SIV) or 182 nt (HIV‑1). The diagram is not drawn to scale. b-1, b-2, c-1, c-2 Reactions were incubated with SIV (b-1, b-2) 
or HIV‑1 substrates (c-1, c-2) and different concentrations of SIV NC or HIV‑1 NC for 30 min at 37 °C and analyzed as described in “Methods” section. 
Representative gels can be found in Additional file 1: Fig. S1. The percent (%) annealed product was plotted against time of incubation. Error bars 
represent the standard deviation (SD) from three or more independent experiments
Table 1 Rates of  (a) annealing (kobs values)
a, (b) strand 
transfer (kobs values)
b
a Rates were determined by fitting the data from Fig. 3b-1, b-2, c-1, c-2 to a 
single exponential equation
b Rates were determined by fitting the data from Fig. 4b, c and Additional file 2: 
Figure S2 to a single exponential equation
c The error determinations represent the SD from three or more independent 
experiments
NC SIV substrates (min−1) HIV‑1 substrates (min−1)
(a)
 SIV (1.25 µM) 0.12 ± 0.016c 0.20 ± 0.021
 HIV‑1 (1.25 µM) 0.39 ± 0.063 0.38 ± 0.035
(b)
 SIV (1.25 µM) 0.087 ± 0.004c 0.064 ± 0.004
 HIV‑1 (1.25 µM) 0.20 ± 0.01 0.17 ± 0.01
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of concentration [58, 65, 66] (Additional file  3: Fig. S3, 
Additional file 4).
The slope of the force-extension curve is measured 
near the midpoint of the transition by averaging over 
the extensions between 0.4 and 0.5  nm/base pair (bp). 
To determine the hysteresis area ratio, we find the linear 
combination of the worm-like chain (WLC) model, which 
describes double-stranded DNA (dsDNA) (Additional 
file  4: Eq.  1), and the freely-jointed chain (FJC), which 
describes single-stranded DNA (ssDNA) (Additional 
file 4: Eq. 2) that intersects the highest extension of the 
data (Additional file 4: Eqs. 3–4). This makes it possible 
to obtain a value for the hysteresis area ratio (Additional 
file 4: Eq. 5) that is independent of how far the DNA is 
stretched for a particular curve. The results of these 
quantitative analyses as a function of concentration are 
shown in Fig.  5b, c. The transition slope measurements 
suggest that SIV and HIV-1 NC have similar binding 
affinities in the nM range, as shown by their nearly iden-
tical equilibrium dissociation constants:  Kd =  5.5 ±  0.4 
and 4.2  ±  0.4  nM, respectively (Fig.  5b). The overall 
maximum transition slope is slightly higher for SIV NC, 
consistent with its slightly stronger intercalative binding 
relative to HIV-1 NC. Analysis of the hysteresis as a func-
tion of concentration also shows that for the lowest con-
centrations tested, HIV-1 NC binding resulted in a larger 
hysteresis area ratio compared to SIV NC. At all other 
concentrations tested, the proteins behaved in a very 
similar manner (Fig. 5c).
The primary difference between HIV-1 NC and SIV 
NC, as observed in single molecule DNA stretching 
experiments, can be seen upon close examination of 
the force-extension curves at low forces and extensions 
(Fig.  6a). To stretch dsDNA at extensions below the 
dsDNA contour length of 0.34 nm/bp in the presence of 
protein, higher forces are needed relative to the “DNA 
only” sample. This additional force at low extensions 
is referred to as the DNA compaction force (Fc). The 
magnitude of the Fc reflects the ability of the protein to 
attract dsDNA, which normally results in DNA aggrega-
tion in the absence of applied force [67, 68]. To quantify 
this compaction force, we used the method described in 
the legend to Fig.  6a. The results showed that the com-
paction force for HIV-1 NC is ~ 2-fold higher than that 
of SIV NC at both 30  nM and 60  nM concentrations 
(Fig.  6b). The additional compaction force for HIV-1 
NC relative to that of SIV NC, averaged over both con-
centrations and weighted by uncertainty, is 1.3 ± 0.4 pN. 
This corresponds to a difference in compaction energy of 
0.11 ± 0.03 kBT/bp. Thus, for a 10 kbp dsDNA molecule, 
similar to the length of the HIV-1 genome, the additional 
compaction energy for HIV-1 NC is 1100 ± 300 kBT, or 
a
b c
Fig. 4 Kinetics of SIV minus‑strand transfer in the presence of SIV and HIV‑1 NC proteins. Reactions were incubated with the indicated concentra‑
tions of SIV or HIV‑1 NC for 60 min at 37 °C and were analyzed as described in “Methods” section. a Representative gels showing DNA species pre‑
sent in reactions with 1.25 µM SIV or HIV‑1 NC. The transfer product (T) and (−) SSDNA are indicated to the left of the gel image and these were the 
only two bands that appeared on the gel. Note that self‑priming products [18, 19, 100, 114] were not formed under the conditions used for these 
assays. Lane c shows the migration of (−) SSDNA in the absence of other reactants. b, c The % strand transfer product formed was plotted against 
time of incubation for reactions with SIV NC (b) or HIV‑1 NC (c). Error bars represent the SD from three or more independent experiments
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640 ± 170 kcal/mol, which is a very large energy differ-
ence for a molecular process.
Analysis of HIV‑1 and SIV NC NA aggregation properties 
by dynamic light scattering (DLS)
The ability of retroviral NC proteins to aggregate NAs is 
important for NC’s NA chaperone function, as well as for 
formation of the ribonucleoprotein complex containing 
gRNA that is located within the mature virion core [18, 
69–72]. We used DLS to characterize the NA aggregate 
size generated by HIV-1 and SIV NCs in the presence of 
SIV Psi RNA (Fig.  7). In addition to the reactions with 
NC, a no NC control was included. The average size of 
the NA aggregate formed in the absence of NC was 
0.74 ± 0.02 nm (n = 4) in diameter and ranged from 0.54 















































Fig. 5 a Force‑extension curves for dsDNA stretch (solid lines) and return (dashed lines) with no protein and in the presence of 30 nM SIV NC or 
HIV‑1 NC. b, c Dependence of the measured transition slope (b) and hysteresis area ratio (c) on protein concentration (see Additional file 4) for 
HIV‑1 NC and SIV NC. The lines in (b) are fits to a simple binding isotherm (Additional file 4: Eq. 6), revealing equilibrium dissociation constants 
Kd = 5.5 ± 0.4 nM for SIV NC and Kd = 4.2 ± 0.4 nM for HIV‑1 NC. Error bars are standard errors for three or more measurements
a b
Fig. 6 a Method for calculating the compaction force (Fc) induced by protein‑DNA interactions. Inset shows stretch (solid lines) and return (dashed 
lines) curves for dsDNA in the absence of protein and in the presence of near saturated (30 nM) HIV‑1 NC protein. Fc is calculated in the low force‑
extension regime denoted within the gray box in the inset and magnified in the main figure. The DNA only extension curve is fit to the WLC model 
(Additional file 4: Eq. 1). The force difference (Fc) between the return curve in the presence of high protein concentration and the DNA only stretch‑
ing curve is averaged over measured extensions <0.31 nm/bp to obtain Fc. b Fc for SIV NC and HIV‑1 NC for concentrations of 30 nM and 60 nM. 
Error bars are standard errors for three or more measurements
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these conditions. In contrast, HIV-1 NC generated aggre-
gates with a mean diameter of 642 ± 60 nm (n = 3) and 
a range from 164 to 1484  nm. These values agree with 
previous reports using different NA substrates [45, 69, 
70]. Interestingly, the range of NA aggregates produced 
by SIV NC was found to be only 106 to 1106  nm, with 
an average size of 448 ± 65 nm (n = 5), which is smaller 
than the corresponding NA aggregates produced by 
HIV-1 NC. Taken together, these data suggest that HIV-1 
NC is a more effective aggregating agent than SIV NC, 
consistent with the Fc measurements (Fig. 6b).
RNA Binding properties of HIV‑1 and SIV NC proteins
Retroviral NC proteins interact with NAs using both spe-
cific and non-specific modes of binding [27]. To evalu-
ate the RNA binding properties of SIV and HIV-1 NCs, 
we examined the interaction of these proteins with four 
RNA constructs: HIV-1 TARpolyA; SIV TAR; HIV-1 Psi; 
and SIV Psi (Fig. 2). Since HIV-1 TARpolyA and SIV TAR 
sequences have been shown to be largely dispensable 
for selective gRNA packaging in HIV-1 and SIV virions, 
respectively, [25, 61, 62, 73, 74], we used these non-Psi 
RNAs to assay non-specific binding.
Fluorescence anisotropy (FA) salt-titration assays have 
previously been shown to be capable of distinguishing the 
relative contribution of specific vs. non-specific or electro-
static interactions for any given NC-RNA binding event 
[27, 75]. Briefly, the FA signal emitted by fluorescently-
labeled RNA is measured at fixed protein and RNA con-
centrations, while the NaCl concentration is varied. As the 
salt concentration increases, less NC is able to bind RNA, 
resulting in a decrease in the FA signal. Thus, a protein-
RNA complex that is more dependent on electrostatic 
interactions than specific contacts, dissociates at lower 
salt concentration relative to a complex that is character-
ized by specific non-electrostatic binding interactions. To 
quantify the results, the data are fit to an equation (see 
“Methods”), which yields the parameters Kd(1M) and Zeff. 
Kd(1M) represents the Kd of the protein-RNA interaction 
when all electrostatic contacts have been screened out and 
only specific ones remain (e.g., hydrogen bonding or aro-
matic stacking interactions). Zeff represents the number of 
Na+ ions displaced from the RNA upon protein binding, 
which corresponds to the number of electrostatic contacts 
made between the protein and the RNA.
We performed FA salt-titration assays using the four 
SIV and HIV-1 RNAs shown in Fig.  2 and the corre-
sponding NC proteins (Additional file  5: Fig. S4a–d). 
HIV-1 NC binding to HIV-1 TARpolyA and Psi sub-
strates was characterized by Kd(1M) values equal to 
1.2 ×  10−4 M and 4.0 ×  10−6 M, respectively, and Zeff 
values equal to 2.4 and 1.2, respectively (Fig. 8; Table 2). 
The significant difference (~30-fold) between the Kd(1M) 
values for the HIV-1 NC-Psi and TARpolyA interactions 
is in general agreement with our previous report and 
shows that NC binds more specifically to Psi RNA rela-
tive to TARpolyA [27]. SIV NC binding to HIV-1 TAR-
polyA and Psi RNAs yielded Kd(1M) values of 8.2 × 10−5 
M and 3.9  ×  10−6 M, respectively, and Zeff values of 
2.1 and 1.3, respectively (Fig.  8; Table  2). These values 
are very similar to the values obtained with HIV-1 NC. 
Comparable binding affinities of HIV-1 and SIV NC to 
SL structures in HIV-1 Psi have also been reported as 
“unpublished results” in Ref. [52]. However, the cur-
rent data also indicate that both proteins bind HIV-1 Psi 
RNA in a more specific, non-electrostatic manner than 
TARpolyA RNA.
In contrast, HIV-1 NC was found to interact with SIV 
TAR and Psi RNAs with very similar Kd(1M) values of 
8.1  ×  10−5 M and 1.0  ×  10−4 M, respectively, and Zeff 
values of 2.6 and 3.6, respectively (Fig.  8; Table  2). SIV 
NC was also unable to effectively discriminate between 
SIV TAR and Psi RNA interactions with Kd(1M) values 
of 6.2 × 10−5 M and 7.2 × 10−5 M, respectively, and Zeff 
values of 2.4 and 3.0, respectively. These results suggest 
that neither HIV-1 nor SIV NC interacts with the SIV Psi 
RNA construct used here with greater specificity than 
with a non-Psi sequence and also show that regardless 
of the RNA substrate tested, both HIV-1 and SIV NCs 
interacted with very similar Kd(1M) and Zeff values (Fig. 8; 
Table 2).
SIV RNA interactions with HIV‑1 Gag
We next wanted to establish whether specific Psi RNA 
recognition in the SIV system requires a Gag polyprotein. 
In earlier work, it was demonstrated that HIV-1 Gag∆p6 
Fig. 7 DLS measurements for HIV‑1 and SIV NC proteins in the pres‑
ence of SIV Psi RNA. The size distributions of NA aggregates formed 
in the presence of the indicated NC or a no NC control are shown. 
Each curve represents the average of at least three independent 
experiments
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binds to HIV-1 Psi RNA with even greater specificity 
than the NC domain alone [27]. It was therefore of inter-
est to test HIV-1 Gag’s binding to SIV Psi versus TAR 
RNA (Fig. 8; Additional file 6: Fig. S5).
In accord with previous results [27], HIV-1 Gag clearly 
exhibited specific binding to HIV-1 Psi versus TARpolyA 
with Kd(1M) values of 1.8 ×  10−4 M and 1.3 ×  10−1 M, 
respectively (Fig. 8a; Table 2). Similarly, Zeff values of 5.0 
and 8.7 for binding to HIV-1 Psi and TARpolyA, respec-
tively (Fig. 8b) were in good agreement with the values 
obtained in the earlier study [27]. In contrast, when 
we tested HIV-1 Gag with SIV TAR and Psi RNAs, the 
Fig. 8 Plot of the parameters determined from measuring the interaction between HIV‑1 NC, SIV NC, and HIV‑1 Gag and the indicated HIV‑1 and 
SIV RNAs as a function of salt concentration. The dark gray circles indicate the fitted a Kd(1M) (M = molarity) and b Zeff parameters from each indi‑
vidual salt‑titration experiment, while each light gray bar is the average of at least three independent trials
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Kd(1M) and Zeff values were very similar: Kd(1M) values of 
1.2 ×  10−1 M and 4.7 ×  10−2 M, respectively, and Zeff 
values of 8.0 and 8.8, respectively (Fig. 8; Table 2). Thus, 
as we found with the NC proteins, HIV-1 Gag was also 
unable to differentiate the SIV Psi RNA construct from 
the non-Psi TAR RNA.
SAXS reveals overall shape of SIV Psi RNA
We considered the possibility that the NC proteins and 
HIV-1 Gag are not able to specifically bind SIV Psi RNA 
due to structural differences between HIV-1 and SIV Psi 
RNAs. The structure of the HIV-1 Psi construct used for 
the current work was previously characterized by SAXS 
[28] and we now applied this approach to SIV Psi. To 
ensure that the RNA was monomeric, the wild-type (WT) 
DIS loop was replaced with a GNRA-type GAGA tetra-
loop (∆DIS mutation, Fig. 2d). SIV Psi-∆DIS was purified 
by size exclusion chromatography (SEC) prior to analysis 
by SAXS. The SEC trace and subsequent analysis by elec-
trophoresis in a native gel (performed concomitantly with 
SAXS data acquisition) confirmed that SIV Psi-∆DIS was 
predominantly monomeric (Additional file 7: Fig. S6a).
Details of the SAXS data analysis and results are given 
in Additional file  7: Fig. S6, Additional file  8: Fig. S7, 
Additional file  9: Table S1, and Additional file  10. The 
SAXS envelope generated for SIV Psi-∆DIS was com-
pared to that of HIV-1 Psi-∆DIS (Additional file  8: Fig. 
S7). As previously reported, all stem-loops of HIV-1 
Psi-∆DIS are solvent exposed and clearly discernable in 
the envelope with apparent co-axial stacking between 
SL1 and SL3 [28]. In contrast, the SIV Psi RNA appears 
more globular and there is no apparent co-axial stack-
ing between the stem-loops. The SAXS data are therefore 
consistent with the conclusion that SIV Psi-∆DIS adopts 
an altered global fold relative to HIV-1 Psi-∆DIS.
Discussion
The goal of the present study was to obtain a detailed 
comparison of the NA chaperone activities of SIV NC 
and the more extensively characterized HIV-1 protein. 
This issue is of great importance in view of the essential 
role of the NC protein in retrovirus replication [18–20, 
76] and the widespread use of simian model systems 
for studies on HIV-1 pathogenesis, vaccine develop-
ment, and drug resistance [77, 78], and more recently, 
the development of HIV-1 eradication and CURE strate-
gies [79]. Here, we focus on two important events in the 
virus life cycle: the minus-strand transfer step in reverse 
transcription that is required for synthesis of a full-length 
copy of the viral RNA genome; and selective gRNA pack-
aging directed by the Psi structural element. Differences 
in the global folds of putative SIV and HIV-1 Psi RNA 
sequences were uncovered in this study, although SIV 
and HIV-1 NC proteins exhibited similar behavior when 
interacting with each of these RNAs. Our results are con-
sistent with the earlier NMR structural study of SIV NC 
[53], as well as with previous functional analysis [52], 
which also came to the conclusion that SIV NC is highly 
similar to the HIV-1 protein. However, we also demon-
strated that despite an overall functional similarity, quan-
titative differences in NA aggregation and compaction 
capability distinguish the two proteins, which may be rel-
evant to the infection process.
In our initial approach, we examined the minus-strand 
transfer reaction, since the rate-limiting step, i.e., anneal-
ing of the complementary R regions, is strongly depend-
ent on NA chaperone activity to transiently destabilize 
the TAR structures and facilitate efficient NA binding. 
Assays of annealing or annealing plus DNA elongation 
(Figs. 3, 4; Additional file 1: Fig. S1, Additional file 2: Fig. 
S2) showed that the SIV NC-mediated reactions occur at 
a 2- to 3-fold slower rate than with HIV-1 NC (Table 1), 
although the extent of product formation after incubation 
for 30 or 60 min is only slightly elevated in the presence 
of HIV-1 NC. To understand the physical basis for this 
behavior, we performed single molecule DNA stretching 
and DLS experiments.
In single molecule stretching determinations, both 
HIV-1 and SIV NC showed very similar NA bind-
ing affinities and qualitative interactions with DNA, 
Table 2 Binding parameters determined from FA salt-titration assays
All values represent the average of at least three trials with the associated standard deviation
a Kd(1M) is the affinity at 1 M NaCl, which represents the specific, non-electrostatic component of binding
b Zeff is the number of Na
+ ions released upon protein binding, and reflects the number of electrostatic contacts between protein and RNA
RNA HIV‑1 NC SIV NC HIV‑1 Gag∆p6
Kd(1M) (M)
a Zbeff Kd(1M) (M)
a Zbeff Kd(1M) (M)
a Zbeff
HIV‑1 TARpolyA (1.2 ± 1.2) × 10−4 2.4 ± 0.4 (8.2 ± 2.3) × 10−5 2.1 ± 0.1 (1.3 ± 0.1) × 10−1 8.7 ± 0.5
HIV‑1 Psi (4.0 ± 2.6) × 10−6 1.2 ± 0.1 (3.9 ± 1.5) × 10−6 1.3 ± 0.1 (1.8 ± 2.0) × 10−4 5.0 ± 2.0
SIV TAR (8.1 ± 6.5) × 10−5 2.6 ± 0.4 (6.2 ± 4.3) × 10−5 2.4 ± 0.3 (1.2 ± 1.9) × 10−1 8.0 ± 1.4
SIV Psi (1.0 ± 0.7) × 10−4 3.6 ± 0.9 (7.2 ± 3.1) × 10−5 3.0 ± 0.3 (4.7 ± 4.0) × 10−2 8.8 ± 1.0
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consistent with their very similar domain structure 
(Fig. 5). However, a more quantitative analysis revealed a 
significant difference in the compaction forces, Fcs, gen-
erated by these two proteins at extensions less than the 
DNA contour length (Fig.  6). The Fcs induced by SIV 
NC were 2-fold lower than those of HIV-1 NC, leading 
to a very large difference in the DNA compaction energy 
for the two proteins. Since the N-terminal domain is 
believed to be a primary determinant for HIV-1 NC’s 
aggregation properties [41], this lower Fc could be due 
to the shorter N-terminal domain of SIV NC, which has 
one less basic residue, relative to that of HIV-1 NC. In 
addition, the ZF linker domain of HIV-1 NC has a much 
higher charge density (5 basic residues) than SIV NC (3 
basic residues), and this is also likely to contribute to the 
stronger aggregation ability of the HIV-1 protein. DLS 
measurements to assess NA aggregate size showed that 
SIV NC produces NA aggregates with a smaller average 
size and smaller size distribution than HIV-1 NC (Fig. 7), 
in excellent agreement with the single molecule stretch-
ing data. Thus, the observed difference in NA chaperone 
activity of HIV-1 NC relative to SIV NC, although mod-
est, is likely due to stronger aggregation and electrostatic 
interaction properties of the HIV-1 protein. Moreover, 
single molecule DNA compaction energy measurements 
suggested that the differences between the NA interac-
tions of HIV-1 NC and SIV NC may be amplified for NA 
chaperone functions involving longer NAs.
The smaller slope of the DNA stretching curves 
observed in the presence of HIV-1 NC compared to SIV 
NC (Fig. 5b), reflects less optimal intercalative binding to 
the DNA duplex. We hypothesize that this may be due to 
the presence of a Trp residue in ZF1 of SIV NC instead of 
the Phe present in HIV-1 NC, and that this subtle differ-
ence may lead to stronger stacking and intercalation. Inter-
estingly, feline immunodeficiency virus (FIV) NC binding 
resulted in an even smaller transition slope than HIV-1 NC 
at all concentrations tested [66]. FIV NC also has one aro-
matic residue in each ZF, but the aromatic residue in ZF2 
is located on the opposite side of the finger relative to that 
on SIV NC and HIV-1 NC. These data suggest that both 
SIV and HIV-1 NC intercalate more strongly than FIV NC, 
consistent with the non-optimal location of the aromatic 
amino acid in ZF2 of the FIV protein [66].
We also showed using a FA salt-titration binding assay 
that HIV-1 and SIV NCs interact with a very similar 
degree of electrostatic versus specific binding contacts, 
independent of the RNA examined. Importantly, like 
HIV-1 NC, SIV NC was capable of interacting with HIV 
Psi RNA using a more specific binding mode (i.e. lower 
Kd(1M)) relative to a non-Psi RNA (HIV-1 TARpolyA) 
(Fig.  8). This finding is consistent with the previous 
observation that SIV proteins are capable of packaging 
and transducing HIV-1 gRNA [80], although a separate 
study reported that HIV-1 gRNA packaging by SIV Gag-
Pol occurred at a reduced efficiency and HIV-1 gRNA 
transfer to SIV target cells was not observed [81]. A 
recent study showed that both HIV-2 NC and HIV-2 
Gag∆p6 preferentially bind HIV-2 Psi RNA [82]. How-
ever, the affinity of Gag for the Psi element is greater 
than that of NC, reflecting contributions from both the 
NC and MA domains in Gag. Interestingly, the mature 
HIV-2 MA protein also has NA chaperone activity, but 
unlike mature HIV-2 NC, is unable to distinguish Psi and 
non-Psi RNAs. Another recent report consistent with 
our results found that the dimerization properties of 
HIV-1 and SIV 5′ leader RNAs are determined by their 
DIS sequence and not by the identity of the NC protein 
(HIV-1 vs. SIV) used to induce dimerization [83]. This 
led the authors to conclude that the HIV-1 and SIV NC 
proteins are functionally equivalent in their ability to pro-
mote RNA dimerization.
In contrast to binding data with HIV-1 Psi, neither SIV 
NC nor HIV-1 NC interacted with the putative SIV Psi 
RNA in the more specific binding mode and the interac-
tion profiles were not readily distinguishable from that 
of either HIV-1 TARpolyA or SIV TAR (Fig. 8; Table 2). 
HIV-1 Gag was also unable to discriminate between SIV 
Psi versus TAR RNAs, even though it bound HIV-1 Psi 
with high specificity. This result is surprising in light of 
reports showing that HIV-1 Gag/GagPol can package 
and propagate SIV gRNA [81, 84]. Taken together, these 
observations suggest that it may be the NA sequence 
that we have selected as “SIV Psi”, rather than an inabil-
ity of SIV NC to make specific NA interactions, which is 
responsible for the lack of observed specificity.
It is important to note that the minimal Psi packaging 
element has not yet been unambiguously identified in 
HIV-1 [25, 30] or SIV [61, 62, 73, 74], as it has for other 
retroviruses such as MLV [85–87] or Rous sarcoma virus 
(RSV) [88–90]. While we derived both HIV and SIV Psi 
constructs used in this work from gRNA regions that 
have been shown in genetic experiments to be neces-
sary for efficient genome packaging, additional sequences 
have been proposed to play a role in HIV-1 [59] and SIV 
[91] gRNA encapsidation. Despite the strong secondary 
structural homology between HIV-1 and SIV Psi [63], 
additional RNA sequences may be required for SIV Psi 
to fold into a well-defined packaging signal in vitro. Con-
sistent with this possibility, the SAXS envelope of SIV Psi 
RNA appears less well defined and differs significantly 
from that of HIV-1 Psi. This is in contrast to MLV Psi, 
which has an overall fold that resembles that of HIV Psi 
[92]. Alternatively, we cannot rule out the possibility that 
SIV Gag is required for specific binding to the SIV Psi 
element. Indeed, we have previously shown that the MA 
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domains of HIV-1 [27] and RSV [93] Gag enhance the 
specificity of binding to their cognate Psi RNAs.
In summary, the functional similarities between HIV-1 
and SIV NC proteins are highlighted in the present work 
by their ability to interact specifically with HIV-1 Psi 
RNA and to effectively discriminate HIV-1 Psi versus 
non-Psi RNAs such as HIV-1 TARpolyA and SIV TAR, 
providing additional mechanistic insight into inter-spe-
cies genomic RNA packaging. Nevertheless, despite the 
high structural and functional homology, our studies 
also clearly reveal subtle differences in the NA chaper-
one functions of HIV-1 and SIV NC proteins that can be 
explained by differences in their NA aggregation capabili-
ties and DNA compaction energies.
Conclusions
Based on biochemical assays and quantitative biophysi-
cal analysis, we demonstrated that despite a high degree 
of similarity between SIV and HIV-1 NC proteins, modest 
differences in their nucleic acid chaperone activities were 
observed, which reflect differences in DNA compaction 
energy and ability to aggregate NAs. In addition, we pro-
vided evidence for specific cross-species recognition of 
the HIV-1 Psi RNA packaging signal. Taken together, the 
vast similarities and only subtle differences observed in 
NC functional assays help to further validate SIV as a use-
ful vehicle for development of new therapeutic strategies 
in the fight against the devastating consequences of AIDS.
Methods
Materials
DNA oligonucleotides and pIDTSMART vectors were 
purchased from Integrated DNA Technologies (IDT) 
(Coralville, IA, USA). [γ-32P]ATP was obtained from 
PerkinElmer (Shelton, CT, USA). HIV-1 RT was pur-
chased from Worthington (Lakewood, NJ, USA). T4 
polynucleotide kinase, proteinase K, SUPERaseIN, and 
Gel Loading Buffer II were bought from Life Technolo-
gies (Foster City, CA, USA). E271 loading dye base was 
obtained from AMRESCO LLC (Solon, OH, USA). The 
Ambion MEGAshortscript T7 kit was purchased from 
Life Technologies. The sequences of the HIV-1 accep-
tor RNA and (−) SSDNA, as well as the TAR and Psi 
RNAs were derived from HIV-1 NL4-3 (GenBank Acces-
sion no. AF324493) [94]. The corresponding SIV NAs 
were derived from SIVmac239 (GenBank Accession no. 
M33262) [12, 13], which was obtained from Dr. Ronald 
Desrosiers through the AIDS Reagent Program, Division 
of AIDS, NIAID, NIH.
Recombinant NC and Gag proteins
HIV-1 recombinant NC proteins were expressed in E. 
coli BL21 (DE3) cells and purified as described previously 
[95, 96]. Essentially the same procedures were used to 
prepare the SIV NC proteins. Briefly, the DNA regions 
encoding the 52-amino-acid sequences from SIVmne 
(Genbank accession no. M32741) [97, 98] or SIVmac239 
[12, 13] were cloned into the pET32a expression vector 
(Novagen, Inc., Madison, WI, USA), expressed in E. coli, 
cleaved from the thioredoxin fusion partner, and purified 
as described [95, 96]. Note that SIVmne and SIVmac239 
NC proteins are identical except for the amino acids at 
positions 27, 38, and 40: the Mne residues are T27, Q38, 
and G40, respectively, whereas the Mac239 residues are 
A27, K38, and D40, respectively. In addition, there is 
functional identity at position 4, with K for Mne and R 
for Mac239. The experiments presented here were per-
formed with SIVmne NC. SIVmac239 NC was used for 
some of the initial minus-strand annealing and strand 
transfer experiments; however, the results obtained with 
either SIV NC were the same within uncertainty (data 
not shown). The charge of each NC protein over a range 
of pH was calculated using the protein calculator at 
http://protcalc.sourceforge.net/. The HIV-1 Gag protein 
lacking the p6 domain (HIV-1 Gag∆p6, also referred to 
simply as “Gag”) was purified as previously described [27, 
99]. The concentration of NC in solution was determined 
by measuring the absorbance at 280 nm using the extinc-
tion coefficients 5680 and 11,560  M−1  cm−1 for HIV-1 
and SIV NCs, respectively, and for Gag, using the extinc-
tion coefficient 63,090 M−1 cm−1.
Synthesis of viral RNA transcripts
The HIV-1 acceptor RNA (RNA 148) was prepared as 
described previously [100, 101]. The sequence of the SIV 
acceptor RNA (RNA 228) consisted of the 52 3′ terminal 
nt in the unique 3′ region (U3) (beginning at nt 10,184) to 
the last nt in R (nt 10,411). It was prepared by performing 
a PCR reaction using the SIV p239SpE3′ plasmid (Gen-
Bank Accession no. M33262) obtained from Dr. Ronald 
Desrosiers through the AIDS Reagent Program, Divi-
sion of AIDS, NIAID, NIH [12, 13]. The dsDNA prod-
uct was run on a 2.5% agarose gel and then gel purified 
prior to transcription with T7 RNA polymerase using the 
MEGAshortscript T7 kit. The SIV acceptor RNA product 
was subjected to electrophoresis in a 6% polyacrylamide 
denaturing gel and then gel purified prior to use in the 
minus-strand annealing and strand transfer assays.
For the salt-titration and SAXS experiments, DNA 
template sequences encoding the T7 RNA polymerase 
promoter sequence followed by the sequences for HIV-1 
viral RNAs (TARpolyA and Psi-WT) were prepared as 
described [27]. DNA template sequences encoding the 
SIV RNAs (TAR and Psi-WT) cloned into pIDTSMART 
vectors were obtained from IDT. The HIV-1 and SIV Psi 
variants with DIS mutated to a GNRA tetraloop sequence 
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(∆DIS) were generated from the Psi-WT plasmids using 
the QuikChange Lightning Site-Directed Mutagen-
esis kit (Agilent Technologies, Santa Clara, CA, USA). 
RNAs were prepared by in vitro transcription and puri-
fied as previously described [102]. Additional non-native 
G residues were added to all RNAs to facilitate efficient 
T7-mediated in  vitro transcription: HIV-1 TARpolyA 
contains one additional G residue, HIV-1 Psi contains two 
additional G residues, SIV TAR contains two additional 
G residues, and SIV Psi contains two additional G resi-
dues. Purified RNAs were fluorescently labeled at their 3´ 
ends with fluorescein-5-thiosemicarbazide (Invitrogen, 
Carlsbad, CA, USA) as described [103, 104]. The RNA 
concentrations in solution were determined by measur-
ing the absorbance at 260 nm, using the following extinc-
tion coefficients: HIV-1 TARpolyA, 935,693  M−1  cm−1; 
HIV-1 Psi-WT, 973,073  M−1  cm−1; HIV-1 Psi-∆DIS, 
926,348  M−1  cm−1; SIV TAR, 1,113,248  M−1  cm−1; 
SIV Psi-WT, 1,318,838  M−1  cm−1; and SIV Psi-∆DIS, 
1,281,458  M−1  cm−1. The extent of labeling with fluo-
rescein was determined by measuring the absorbance at 
495 nm and ε495 = 85,000 M−1 cm−1.
Minus‑strand annealing assay
A 196-nt DNA (DNA 196) (SIV) or a 128-nt DNA (DNA 
128) (HIV-1) representing (−) SSDNA (0.2  pmol), 
labeled at its 5′ end with 32P [105, 106], was incubated 
at 37 °C with 0.4 pmol of acceptor RNA (RNA 228, SIV; 
RNA 148, HIV-1) in buffer containing 50 mM Tris–HCl 
(pH 8.0) and 75 mM KCl and the indicated concentra-
tions of SIV or HIV-1 NC (final volume, 20  µl). Each 
substrate was tested with the same concentrations of 
SIV and HIV-1 NC. However, higher concentrations 
of both NCs were used for the SIV substrates, which 
were significantly longer than the HIV-1 substrates. 
The standard reaction was scaled up as needed and 
15-µl portions were removed at intervals between 1 
and 30  min. Reactions were terminated by addition of 
sodium dodecyl sulfate to a final concentration of 1% 
(vol/vol). The mixtures were placed on ice for 5  min 
and then extracted once with phenol/chloroform. Four 
µl of loading dye mix containing 12.5% glycerol (vol/
vol) and 1x E271 loading dye base were added to 10 µl 
of the aqueous layer and an 8-µl portion was loaded 
onto a native 6% polyacrylamide gel prepared with a 
4% stacking gel. Analysis of the gel data and calculation 
of the percent (%) annealed DNA were performed as 
described previously [107]. Note that to obtain efficient 
annealing and minus-strand transfer in the SIV system, 
the ratio of acceptor RNA to (−) SSDNA normally used 
in our HIV-1 system [100, 101] was increased from 1:1 
to 2:1. For comparison, identical conditions were used 
for the HIV-1 system.
Minus‑strand transfer assay
Reaction mixtures containing reaction buffer (50  mM 
Tris–HCl (pH 8.0), 75  mM KCl, 1  mM dithiothreitol 
[DTT]), 0.2 pmol (−) SSDNA (DNA 196, SIV; DNA 128, 
HIV-1) labeled at its 5′ end with 32P, 0.4  pmol accep-
tor RNA (RNA 228, SIV; RNA 148, HIV-1), and SIV or 
HIV-1 NC as specified, were incubated for 5 min at 37 °C. 
HIV-1 RT (1 pmol) and 0.5 units SUPERaseIN were then 
added and the entire mixture was incubated for another 
5 min at 37 °C. Reactions (final volume, 20 µl) were ini-
tiated by addition of 100  μM each of the four dNTPs, 
and 1  mM MgCl2. The standard reaction was scaled up 
as needed. Incubation was at 37  °C and 10-µl portions 
of the reaction mixture were removed at the indicated 
times. Reactions were terminated by addition of 4  µl of 
Gel Loading Buffer II. Polyacrylamide gel electrophoresis 
in 6% denaturing gels and PhosphorImager analysis were 
performed as described previously [107]. The % strand 
transfer product formed was calculated by dividing the 
amount of transfer product by the total signal in the gel 
lane and multiplying by 100 [108].
Single molecule DNA stretching experiments
A biotinylated bacteriophage λ DNA molecule was teth-
ered in between two streptavidin-coated polystyrene 
beads, torsionally unconstrained by its opposite ends. 
One bead was held in an optical trap, while the other 
was immobilized on a micropipette tip attached to a flow 
cell placed on a translational piezoelectric stage [109]. 
By gradually moving the fixed bead while recording the 
extension and the force exerted on the single DNA mol-
ecule, the force-extension profile of a dsDNA in the 
absence of protein was obtained. The buffer surrounding 
the DNA molecule was then exchanged for a solution of 
fixed HIV-1 or SIV NC protein concentration to obtain 
the force–extension curves in the presence of protein at 
a 100 nm/s pulling rate. The experiments were conducted 
in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 50 mM Na+ buffer solution at pH 7.5.
DLS measurements
DLS experiments were performed using 100  nM SIV 
Psi RNA in buffer containing 50  mM HEPES (pH 7.5), 
5 mM DTT, 1.3 mM MgCl2, and 20 mM NaCl buffer. NC 
(1.2 µM) was added to the reaction mix and incubated at 
room temperature for 30 min prior to DLS measurement 
on a Zetasizer Nano-ZS instrument (Malvern Instru-
ments Ltd, Malvern, Worcestershire, UK). Data were 
analyzed using the Dispersion Technology Software pro-
vided by the manufacturer, and sizes were plotted as vol-
ume percent versus particle size. The average size of the 
aggregate population produced was calculated by taking 
the product of the aggregate volume at each particle size 
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sampled and averaging over the total volume of the pop-
ulation. The average diameter was calculated as the mean 
of 3–5 measurements with the standard error indicated.
FA salt‑titration binding assays
The salt-titration binding assays were performed essen-
tially as previously described [27, 75]. Briefly, a fixed 
concentration of either HIV-1 or SIV NC (400 nM) was 
incubated with refolded RNA (10  nM) in increasing 
NaCl concentrations (30–750 mM) together with 20 mM 
HEPES (pH 7.5), 20 µM Tris-(2-carboxyethyl)-phosphine, 
5 mM 2-mercaptoethanol, and 1 mM MgCl2. RNAs were 
refolded in 50 mM HEPES (pH 7.5) by heating at 80  °C 
for 2 min and then at 60 °C for 2 min, followed by addi-
tion of 10 mM MgCl2 and incubation on ice for at least 
30 min. The reactions were incubated at room tempera-
ture in the dark for 30  min and then FA was measured 
using a SpectraMax M5 plate reader (Molecular Devices, 
Sunnyvale, CA, USA). Gag salt-titration assays were per-
formed using the same protocol, except that 20 nM RNA 
was used and the reaction buffer also contained 2  mM 
Tris–HCl, pH 7.4. To correct for the effect of increas-
ing NaCl on RNA anisotropy independent of protein 
binding, separate salt-titration assays of the RNA in the 
absence of protein were carried out with every trial. The 
no protein control values were then subtracted from the 
data obtained for protein-containing reactions. The cor-
rected data were then analyzed as described [27, 75]. 
Briefly, the dissociation constant Kd varies as a function 
of Na+ ion concentration as follows:
In Eq. 1, Kd(1M) is the dissociation constant of the RNA–
protein interaction at 1  M NaCl when all electrostatic 
charges have been screened out, thereby reflecting the 
strength of the non-electrostatic binding contacts. Zeff 
represents the number of electrostatic contacts involved 
in the interaction. Substituting Eq. 1 into the binding iso-
therm as previously described [27] allows determination 
of the two parameters, Kd(1M) and Zeff.
Preparation of RNA for SAXS analysis
SIV Psi-∆DIS RNA (450  µg) was refolded as described 
above, except that an additional step of incubation at 
37 °C for 5 min was added between the addition of MgCl2 
and incubation on ice. The folded RNA was then purified 
via SEC on a 24-ml Superdex 200 10/300 GL Increase col-
umn (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK) in running buffer containing 150 mM NaCl, 50 mM 
HEPES (pH 7.4), 1 mM MgCl2, and 3% glycerol (wt/vol) 
at a flow rate of 1 ml/min. Peak fractions containing the 
(1)Kd = Kd(1M) · [Na]
Zeff,
desired RNA were pooled and concentrated to 70–90 µl 
using an Amicon 0.5-ml 10  K molecular weight cutoff 
spin concentrator (EMD Millipore, Bellerica, MA, USA). 
Sample concentrations ranged from 3.0 to 3.7 µg/µl. The 
SEC running buffer was used to serially dilute the RNAs, 
yielding three sample concentration ranges (3.0–3.7, 1.5–
1.9, and 0.75–0.93  µg/µl). An aliquot of the SEC buffer 
used to purify the RNAs was saved for use in SAXS for 
buffer subtraction.
SAXS data acquisition and analysis
Samples were shipped in 96-well plates (Axygen Sci-
entific, Union City, CA, USA) at 4  °C to the 12.3.1 
SIBYLS beamline at the Advanced Light Source (Law-
rence Berkeley National Lab, Berkeley, CA, USA) [110, 
111]. Scattering data were acquired and buffer sub-
traction was performed by the SIBYLS beamline staff 
as described [111, 112]. Subsequent data analysis and 
ab  initio envelope generation were performed largely 
as previously described [28]. Briefly, the SAXS data 
collected at different exposure times for a given con-
centration of sample were examined separately and 
exposures with clear evidence of radiation damage 
were discarded. High quality exposures for each RNA 
concentration dilution were merged and then analyzed 
using Guinier analysis [110] to calculate the radius of 
gyration (Rg) and the extrapolated scattering intensity 
at zero scattering angle (I0) using the program PRI-
MUS [113]. Kratky analysis [110] was also performed 
for each RNA concentration dilution to confirm the 
extent of folding. If the Rg was found to increase upon 
increasing RNA concentration (indicative of concen-
tration-dependent effects) or if the Kratky plots sug-
gested that the RNA was not well folded, the data were 
not analyzed further. If samples passed these qual-
ity control analyses, then the data sets from the three 
concentration dilutions were scaled and merged into 
a single curve. The inter-electron P(r) functions were 
calculated using the program GNOM [113]. The maxi-
mum inter-electron distance (Dmax) was varied until 
the P(r) decayed smoothly to zero and the experimen-
tal data fit well. The Dmax was increased by 2 Å incre-
ments up to 15  Å above the Dmax initially selected by 
the GNOM program. Then for each of these Dmax 
values, five ab  initio envelopes were generated in fast 
mode with no symmetry restraints imposed using the 
ATSAS suite of programs as described [28, 113]. The 
average χ2 fit of the five envelopes to the experimental 
data was determined and the Dmax condition that gave 
the best fit was chosen for further analysis. Using this 
Dmax, 20 ab  initio envelopes were generated using the 
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same protocol as described above, and the χ2 fits and 
reproducibility (NSD) values were calculated. These 20 
envelopes were averaged into one envelope, which was 
then packed with at least 20,000 “dummy atoms” and 
used as the starting point for an additional 24 ab initio 
envelope calculations, generated in jagged mode with 
no symmetry restraints imposed. These envelopes were 
averaged to generate the final envelope and their χ2 fits 
and NSD values were determined.
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of the SAXS data fits well to a linear regression (red line) with low residuals 
(green line), indicating that the SIV Psi‑∆DIS sample is not aggregated. c 
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